Nova Eye Medical Limited designs, develops, distributes, markets, sells, and services medical devices to treat eye diseases.
Nova Eye Medical Competitors
Price History & Performance
|Historical stock prices|
|Current Share Price||AU$0.39|
|52 Week High||AU$0.29|
|52 Week Low||AU$0.58|
|1 Month Change||-10.47%|
|3 Month Change||26.23%|
|1 Year Change||16.67%|
|3 Year Change||-53.33%|
|5 Year Change||-65.00%|
|Change since IPO||-35.06%|
Recent News & Updates
Nova Eye Medical (ASX:EYE) Shares Have Generated A Total Return Of Negative 19% In The Last Three Years
Nova Eye Medical Limited ( ASX:EYE ) shareholders should be happy to see the share price up 13% in the last quarter...
|EYE||AU Medical Equipment||AU Market|
Return vs Industry: EYE exceeded the Australian Medical Equipment industry which returned 8.4% over the past year.
Return vs Market: EYE underperformed the Australian Market which returned 25.6% over the past year.
Stable Share Price: EYE is not significantly more volatile than the rest of Australian stocks over the past 3 months, typically moving +/- 9% a week.
Volatility Over Time: EYE's weekly volatility (9%) has been stable over the past year.
About the Company
Nova Eye Medical Limited designs, develops, distributes, markets, sells, and services medical devices to treat eye diseases. The company offers iTrack, a surgical system for the reduction of intraocular pressure (IOP) in adult patients with mild to moderate glaucoma openangle glaucoma; Molteno3, a glaucoma drainage device to treat patients with severe or complex glaucoma; and 2RT, a proprietary laser technology to treat patients in early/intermediate age-related macular degeneration. It operates in Australia, the United States, Europe, the Middle East, Japan, Asia, South America, and internationally.
Nova Eye Medical Fundamentals Summary
|EYE fundamental statistics|
Is EYE overvalued?See Fair Value and valuation analysis
Earnings & Revenue
|EYE income statement (TTM)|
|Cost of Revenue||AU$2.24m|
Last Reported Earnings
Jun 30, 2021
Next Earnings Date
|Earnings per share (EPS)||-0.03|
|Net Profit Margin||-32.04%|
How did EYE perform over the long term?See historical performance and comparison
Is Nova Eye Medical undervalued compared to its fair value and its price relative to the market?
Price to Book (PB) ratio
Share Price vs. Fair Value
Below Fair Value: Insufficient data to calculate EYE's fair value to establish if it is undervalued.
Significantly Below Fair Value: Insufficient data to calculate EYE's fair value to establish if it is undervalued.
Price To Earnings Ratio
PE vs Industry: EYE is unprofitable, so we can't compare its PE Ratio to the Australian Medical Equipment industry average.
PE vs Market: EYE is unprofitable, so we can't compare its PE Ratio to the Australian market.
Price to Earnings Growth Ratio
PEG Ratio: Insufficient data to calculate EYE's PEG Ratio to determine if it is good value.
Price to Book Ratio
PB vs Industry: EYE is good value based on its PB Ratio (1.6x) compared to the AU Medical Equipment industry average (4.9x).
How is Nova Eye Medical forecast to perform in the next 1 to 3 years based on estimates from 0 analysts?
Forecasted Healthcare industry annual growth in earnings
In this section we usually present revenue and earnings growth projections based on the consensus estimates of professional analysts to help investors understand the company’s ability to generate profit. But as Nova Eye Medical has not provided enough past data and has no analyst forecast, its future earnings cannot be reliably calculated by extrapolating past data or using analyst predictions.
This is quite a rare situation as 97% of companies covered by SimplyWall St do have past financial data.
How has Nova Eye Medical performed over the past 5 years?
Historical annual earnings growth
Earnings and Revenue History
Quality Earnings: EYE is currently unprofitable.
Growing Profit Margin: EYE is currently unprofitable.
Past Earnings Growth Analysis
Earnings Trend: EYE is unprofitable, and losses have increased over the past 5 years at a rate of 41.5% per year.
Accelerating Growth: Unable to compare EYE's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: EYE is unprofitable, making it difficult to compare its past year earnings growth to the Medical Equipment industry (57.5%).
Return on Equity
High ROE: EYE has a negative Return on Equity (-12.33%), as it is currently unprofitable.
How is Nova Eye Medical's financial position?
Financial Position Analysis
Short Term Liabilities: EYE's short term assets (A$26.3M) exceed its short term liabilities (A$4.7M).
Long Term Liabilities: EYE's short term assets (A$26.3M) exceed its long term liabilities (A$2.0M).
Debt to Equity History and Analysis
Debt Level: EYE's debt to equity ratio (4%) is considered satisfactory.
Reducing Debt: EYE's debt to equity ratio has reduced from 16% to 4% over the past 5 years.
Cash Runway Analysis
For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.
Stable Cash Runway: EYE has sufficient cash runway for more than a year based on its current free cash flow.
Forecast Cash Runway: EYE has less than a year of cash runway if free cash flow continues to reduce at historical rates of 8.7% each year
What is Nova Eye Medical current dividend yield, its reliability and sustainability?
Dividend Yield vs Market
Notable Dividend: Unable to evaluate EYE's dividend yield against the bottom 25% of dividend payers, as the company has not reported any recent payouts.
High Dividend: Unable to evaluate EYE's dividend yield against the top 25% of dividend payers, as the company has not reported any recent payouts.
Stability and Growth of Payments
Stable Dividend: Insufficient data to determine if EYE's dividends per share have been stable in the past.
Growing Dividend: Insufficient data to determine if EYE's dividend payments have been increasing.
Current Payout to Shareholders
Dividend Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.
Future Payout to Shareholders
Future Dividend Coverage: No need to calculate the sustainability of EYE's dividend in 3 years as they are not forecast to pay a notable one for the Australian market.
How experienced are the management team and are they aligned to shareholders interests?
Average management tenure
Nova Eye Medical has no CEO, or we have no data on them.
Experienced Management: EYE's management team is considered experienced (2.9 years average tenure).
Experienced Board: EYE's board of directors are considered experienced (8.3 years average tenure).
Who are the major shareholders and have insiders been buying or selling?
Insider Trading Volume
Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.
Recent Insider Transactions
Dilution of Shares: Shareholders have not been meaningfully diluted in the past year.
Nova Eye Medical Limited's employee growth, exchange listings and data sources
- Name: Nova Eye Medical Limited
- Ticker: EYE
- Exchange: ASX
- Founded: 1985
- Industry: Health Care Equipment
- Sector: Healthcare
- Market Cap: AU$56.038m
- Shares outstanding: 145.55m
- Website: https://www.nova-eye.com
Number of Employees
- Nova Eye Medical Limited
- 107 Rundle Street
- Kent Town
- South Australia
Company Analysis and Financial Data Status
|Data||Last Updated (UTC time)|
|Company Analysis||2021/09/16 04:28|
|End of Day Share Price||2021/09/15 00:00|
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.